Obesity does not adversely affect outcomes after laparoscopic splenectomy

Heneghan, Helen; Annaberdyev, Shohrat; Attaluri, Vikram; Pitt, Tracy; Kroh, Matthew; Chalikonda, S.; Brethauer, Stacy A.; Rosenblatt, Steven

doi:10.1016/j.amjsurg.2012.07.041

Cited by 6 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shortening of the colon was reported also in ulcerative colitis patients (Gore 1992), and was explained in terms of enlargement and contraction of the muscolaris mucosae, but the mechanisms remain unclear (Gore 1992). Splenomegaly is associated with intestinal inflammation in animal models of IBD (Wirtz et al 2007;Chassaing et al 2014) and it has been reported also among obese patients (Heneghan et al 2013) and HF diet-fed rodents (Altunkaynak et al 2007;Aboura et al 2017;de Jesus Felismino et al 2018).…”

Section: Pops Promote Intestinal Inflammationmentioning

confidence: 99%

Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice

Benoit

Meugnier

Castelli

et al. 2017

Nat Med

178

163

View full text Add to dashboard Cite

The endocrine-derived hormone fibroblast growth factor (FGF) 19 has recently emerged as a potential target for treating metabolic disease. Given that skeletal muscle is a key metabolic organ, we explored the role of FGF19 in that tissue. Here we report a novel function of FGF19 in regulating skeletal muscle mass through enlargement of muscle fiber size, and in protecting muscle from atrophy. Treatment with FGF19 causes skeletal muscle hypertrophy in mice, while physiological and pharmacological doses of FGF19 substantially increase the size of human myotubes in vitro. These effects were not elicited by FGF21, a closely related endocrine FGF member. Both in vitro and in vivo, FGF19 stimulates the phosphorylation of the extracellular-signal-regulated protein kinase 1/2 (ERK1/2) and the ribosomal protein S6 kinase (S6K1), an mTOR-dependent master regulator of muscle cell growth. Moreover, mice with a skeletal-muscle-specific genetic deficiency of β-Klotho (KLB), an obligate co-receptor for FGF15/19 (refs. 2,3), were unresponsive to the hypertrophic effect of FGF19. Finally, in mice, FGF19 ameliorates skeletal muscle atrophy induced by glucocorticoid treatment or obesity, as well as sarcopenia. Taken together, these findings provide evidence that the enterokine FGF19 is a novel factor in the regulation of skeletal muscle mass, and that it has therapeutic potential for the treatment of muscle wasting.

show abstract

Section: Pops Promote Intestinal Inflammationmentioning

confidence: 99%

Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice

Benoit

Meugnier

Castelli

et al. 2017

Nat Med

178

163

View full text Add to dashboard Cite

show abstract

“…These parenchymal changes are associated with increased morbidity after hepatic resection 13,14 . The laparoscopic approach in obese patients has not been associated with adverse outcomes in a number of general surgical procedures, but has not been convincingly shown in LLR 5–7,23–26 . Existing studies in OLR and transplant show conflicting results 27–29 .…”

Section: Discussionmentioning

confidence: 99%

Body mass index and surgical outcomes in laparoscopic liver resections: a systematic review

Kwan

Waters

Keogh

et al. 2021

ANZ Journal of Surgery

View full text Add to dashboard Cite

Background Laparoscopic liver resection is gaining momentum; however, there is limited evidence on its efficacy and safety in obese patients. The aim of this study was to examine the relationship between BMI and outcomes after laparoscopic liver resection (LLR) using a systematic review of the existing literature. Methods A systematic search of Medline (Ovid 1946–present), PubMed (NCBI), Embase (Ovid 1966–present) and Cochrane Library was conducted using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement for parameters of LLR and BMI. Operative, post‐operative and oncological outcomes were recorded. Results Of 1460 abstracts, seven retrospective studies were analysed, published between 2015 and 2017 (study periods 1998–2017). Total patient cohort were classified as 481 obese and 1180 non‐obese with a median age range of 42.5–69.4 years. Variations existed in definitions of obesity (Asia BMI >25 kg/m2, Western BMI >30 kg/m2). Rates of conversion were examined in four studies (0–31%) with one reporting BMI >28 kg/m2 as an independent risk factor. Estimated blood loss and transfusion rates were similar. Operative time was increased in obese patients in one study (P = 0.02). Mortality rates ranged from 0% to 4.3% with no difference between BMI classes. No difference in major morbidity was demonstrated. Bile leak rates were increased in obese groups in one study (0–3.44%, P < 0.05). Wound infections were reported in five studies, with higher rates in obese patients (0–5.8% versus 0–1.9%). Tumour size was comparable in both groups. Completeness of resection was analysed in four studies with one study reporting increased R0 rates in obese patients (P = 0.012). Conclusion This systematic review highlights that current evidence shows LLR in obese patients is safe, however, further studies are required.

show abstract

Laparoscopic Splenectomy: Perioperative Management, Surgical Technique, and Results

Fisichella¹,

Wong²,

Pappas³

2014

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

Since their introduction in the early 1990s, minimally invasive techniques have gained widespread acceptance because of the significant benefits that patients are able to experience. Some of these benefits include reduced postoperative pain, earlier return to normal activity, and improved cosmesis when compared with open surgery. For these reasons, since its first description by Delaitre and Maignien in 1991, laparoscopic splenectomy (LS) has been increasingly utilized for a safe surgical removal of the spleen with nearly equivalent or superior short- and long-term outcomes when compared with the open approach. In this technical report, we aim to describe our preoperative and postoperative management of patients undergoing LS and to illustrate our preferred surgical technique, its rationale, and our results.

show abstract

Obesity does not adversely affect outcomes after laparoscopic splenectomy

Cited by 6 publications

References 31 publications

Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice

Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice

Body mass index and surgical outcomes in laparoscopic liver resections: a systematic review

Laparoscopic Splenectomy: Perioperative Management, Surgical Technique, and Results

Contact Info

Product

Resources

About